1 reports of this reaction
11.1% of all MAGNESIUM SULFATE, UNSPECIFIED FORM reports
#9 most reported adverse reaction
TACHYCARDIA is the #9 most commonly reported adverse reaction for MAGNESIUM SULFATE, UNSPECIFIED FORM, manufactured by ANI Pharmaceuticals, Inc.. There are 1 FDA adverse event reports linking MAGNESIUM SULFATE, UNSPECIFIED FORM to TACHYCARDIA. This represents approximately 11.1% of all 9 adverse event reports for this drug.
Patients taking MAGNESIUM SULFATE, UNSPECIFIED FORM who experience tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TACHYCARDIA is a frequently reported adverse event for MAGNESIUM SULFATE, UNSPECIFIED FORM, accounting for a significant proportion of all reports.
In addition to tachycardia, the following adverse reactions have been reported for MAGNESIUM SULFATE, UNSPECIFIED FORM:
The following drugs have also been linked to tachycardia in FDA adverse event reports:
TACHYCARDIA has been reported as an adverse event in 1 FDA reports for MAGNESIUM SULFATE, UNSPECIFIED FORM. This does not prove causation, but indicates an association observed in post-market surveillance data.
TACHYCARDIA accounts for approximately 11.1% of all adverse event reports for MAGNESIUM SULFATE, UNSPECIFIED FORM, making it a notable side effect.
If you experience tachycardia while taking MAGNESIUM SULFATE, UNSPECIFIED FORM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.